Requested actions
-
- Be aware, on April 25, 2022, Centers for Disease Control and Prevention (CDC) issued a Health Alert Network (HAN) advisory about the availability and use of recommended COVID-19 therapies. It also advised against using unproven treatments that have known or potential harm.
- Follow National Institutes of Health (NIH) COVID-19 treatment guidelines and use recommended treatment options to treat patients who:
- Have mild to moderate COVID-19, and
- Are not hospitalized, and
- Are at increased risk of severe COVID-19 outcomes.
- Do not offer systemic corticosteroids to patients with mild to moderate COVID-19 who do not require supplemental oxygen as they have no proven benefit and can cause harm. Patients receiving dexamethasone or other corticosteroids for other indications should continue therapy as directed by their healthcare provider.
- Do not use antibacterial therapy to treat COVID-19 as they have no benefit and can cause harm.
- Continue to promote up-to-date COVID-19 vaccination. It remains the best way to prevent severe disease, hospitalization and death.
- Encourage patients who are immunocompromised or severely allergic to COVID-19 vaccine to receive tixagevimab co-packaged with colgavimab (Evusheld). It is a long-acting combination monoclonal antibody therapy given by intramuscular injection for COVID-19 pre-exposure prophylaxis. Use COVID-19 therapeutics locator to find Evusheld distribution sites.
- Follow National Institutes of Health (NIH) COVID-19 treatment guidelines and use recommended treatment options to treat patients who:
- Be aware, on April 25, 2022, Centers for Disease Control and Prevention (CDC) issued a Health Alert Network (HAN) advisory about the availability and use of recommended COVID-19 therapies. It also advised against using unproven treatments that have known or potential harm.
-
- Be aware, on April 20, 2022, CDC’s Advisory Committee on Immunization Practices (ACIP) discussed those who are eligible to get a second booster dose of COVID-19 vaccine (i.e., 50 years or older; 12 years or older and moderately to severely immunocompromised; got Johnson & Johnson vaccine for their primary series and first booster). It is especially important for these people to get a second booster dose if they:
- Have certain medical conditions that increase the risk of severe disease.
- Are moderately or severely immunocompromised.
- Live with a person who is immunocompromised, at increased risk of severe disease, or cannot get COVID-19 vaccine because of age or contraindication.
- Are at increased risk of COVID-19 exposure because of occupational, institutional or other activities.
- Live or work in an area with medium or high COVID-19 community level.
- Be aware, on April 20, 2022, CDC’s Advisory Committee on Immunization Practices (ACIP) discussed those who are eligible to get a second booster dose of COVID-19 vaccine (i.e., 50 years or older; 12 years or older and moderately to severely immunocompromised; got Johnson & Johnson vaccine for their primary series and first booster). It is especially important for these people to get a second booster dose if they:
- Connect patients to free COVID-19 testing locations to help them get COVID-19 medication for free, no insurance needed.
Background
Early outpatient treatment of COVID-19 can prevent serious, potentially life-threatening illness and reduce burden on the healthcare system. CDC issued a HAN advisory on Dec. 31, 2021 to address using therapeutics in the outpatient setting for people with COVID-19. At that time, Omicron cases were rapidly increasing in the United States and some therapeutics were in short supply. Now antivirals for COVID-19 are widely available and accessible by prescription at pharmacies and Test-to-Treat locations nationwide.
Data from CDC (highlighted in a Feb. 13, 2021 CDC Infectious Diseases Society of America COVID-19 clinical call) and Food and Drug Administration (FDA) suggest use of systemic corticosteroids and antibiotics to treat outpatients with COVID-19 is increasing. However, these drugs can cause harm and provide no demonstrated benefit in patients with COVID-19 with no supplemental oxygen requirement or bacterial coinfection. Systemic corticosteroid short courses are associated with adverse events like hyperglycemia, gastrointestinal bleeding, psychosis, infection and long-term effects.
NIH provides COVID-19 treatment guidelines. The guidelines panel provides treatment options and recommends against using systemic corticosteroids to treat patients with mild to moderate COVID-19 who do not require supplemental oxygen. Patients who receive dexamethasone or other corticosteroids for other indications should continue therapy as directed by their healthcare provider. NIH recommends systemic corticosteroids for hospitalized patients with COVID-19 who require supplemental oxygen or higher-level respiratory support.
The guidelines panel also recommends against using antibacterial therapy for COVID-19 in the absence of another indication. Antibacterial drugs have no benefit in treating viral infections and can cause harm.
More information
- COVID-19 treatment page, CDC.
- COVID-19 treatment guidelines, NIH.
- Therapeutic management of non-hospitalized adults with COVID-19, NIH.
- Interim clinical considerations for use of COVID-19 vaccines, CDC.
- Prevention of SARS-CoV-2 infection, NIH.
- Test-to-Treat page, Office of the Assistant Secretary for Preparedness and Response.
- COVID-19 therapeutic product emergency use authorizations (EUAs), FDA.
- COVID-19 data tracker, CDC.
COVID-19 vaccine information
- Clinical considerations for the use of COVID-19 vaccine, CDC.
- Clinician outreach and communication activity (COCA) call slides, CDC.
- Booster dose updates, FDA.
- EUA and FDA-approved vaccine information:
- Pfizer (Comirnaty).
- Moderna (Spikevax).
- Johnson & Johnson.
- COVID-19 vaccine locator, DOH.
- COVID-19 vaccine provider toolkit and resources, DOH.
- COVID-19 vaccination for providers, CDC.
- Clinical considerations for COVID-19 vaccination and guidance for managing anaphylaxis, CDC.
- COVID-19 vaccine quick reference guide for healthcare professionals, CDC.
- COVID-19 vaccine training module on best practices for providers, CDC.
COVID-19 testing
COVID-19 test processing
Labs report varying amounts of time to process COVID-19 tests. To support faster turnaround, we encourage providers to use in-state labs. The table below shows COVID-19 test processing times for in-state private labs.
| Lab | Time to process test | Tests processed daily |
|---|---|---|
| FidaLab | 24 hours | 300 |
| Kaiser | 24–48 hours | 3,000 |
| LabCorp | 24–48 hours | Unknown |
| Northwest Pathology | 12–24 hours | 3,000 |
| Quest | 24–48 hours | 700 |
| UW Virology | 24–72 hours | 5,000–7,000 |
| Atlas Genomic | 24–48 hours | 10,000 |
COVID-19 therapies
Department of Health and Human Services (HHS) allocates monoclonal antibodies and oral antivirals to each state. DOH distributes doses to enrolled providers. Providers must enroll in Healthcare Partner Ordering Portal (HPoP) to manage COVID-19 therapies. Email mcm@doh.wa.gov for support enrolling.
Once enrolled, to request a supply of monoclonal antibodies or therapeutics, complete a smart sheet. Providers can now order treatments directly through HPoP.
Additional information
- COVID-19 therapeutics locator for providers, HHS.
- Therapeutics for providers page, DOH.
- Our COVID-19 treatment information for providers page.
- COVID-19 therapeutics resources, HHS.
- COVID-19 treatment guidelines, NIH.
COVID-19 prevention
Share with patients:
- What to do if you test positive for COVID-19, DOH.
- What to do if you were exposed to someone with COVID-19, DOH.
Immediately report COVID-19
Providers must fax positive lab results with demographic information to 509-381-3526.
Contacting the Health Department
Questions? Contact Yakima Health District at (509) 575-4040 or (800) 535-5016.